Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients

Nai Shun Yao, Yi Ying Wu, Anthony J. Janckila, Chih Hung Ku, An Tai Hsieh, Ching Liang Ho, Su Huei Lee, Tsu Yi Chao

Research output: Contribution to journalArticle

23 Citations (Scopus)


Background: Diagnosis and follow-up of bone metastasis (BMet) in non-small cell lung cancer (NSCLC) patients usually rely on symptoms and image studies. A serum marker of bone resorption may improve the quality of treatment in such patients. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker for osteoclasts and we proposed it can be used as a marker of BMet in NSCLC patients. Methods: In November 2002 till August 2008 serum samples were obtained from 141 newly diagnosed stage IIIA, IIIB or IV NSCLC patients and 41 normal subjects. All patients received baseline bone scintinography examination and evaluation of clinical symptoms as a standard of BMet diagnosis. Patients were divided into 2 groups by having BMet (Group I, n= 72) or not (Group II, n= 69). An in-house immunoassay using a TRACP-specific monoclonal antibody, 14G6, was used to measure the serum TRACP5b activity at pH 6.1. Results: The mean serum TRACP5b activities of Group I, Group II and normal subjects were 3.50. ±. 2.23. U/l, 2.09. ±. 0.72. U/l and 2.33. ±. 0.52. U/l, respectively. After adjusting for age, stage, gender, and histology in a generalized linear model, Group I has significantly higher TRACP5b activity than Group II (p

Original languageEnglish
Pages (from-to)181-185
Number of pages5
JournalClinica Chimica Acta
Issue number1-2
Publication statusPublished - Jan 14 2011



  • Bone metastasis
  • Lung cancer
  • Osteoclast
  • Tartrate-resistant acid phosphatase 5b

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this